NeoGenomics Inc to Present at J.P. Morgan Healthcare Conference
NEO Stock | USD 18.61 0.25 1.36% |
About 55% of NeoGenomics' investors are presently thinking to get in. The analysis of overall sentiment of trading NeoGenomics stock suggests that some investors are interested at this time. NeoGenomics' investing sentiment overview a quick insight into current market opportunities from investing in NeoGenomics. Many technical investors use NeoGenomics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
NeoGenomics |
Summary NeoGenomics Inc , a prominent player in oncology testing services, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Confer
Read at gurufocus.com
NeoGenomics Fundamental Analysis
We analyze NeoGenomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoGenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoGenomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
NeoGenomics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
NeoGenomics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeoGenomics stock to make a market-neutral strategy. Peer analysis of NeoGenomics could also be used in its relative valuation, which is a method of valuing NeoGenomics by comparing valuation metrics with similar companies.
Peers
NeoGenomics Related Equities
CDNA | Caredx | 5.63 | ||||
NTRA | Natera | 3.64 | ||||
MYGN | Myriad Genetics | 3.36 | ||||
CSTL | Castle Biosciences | 1.71 | ||||
GH | Guardant Health | 1.22 | ||||
IQV | IQVIA Holdings | 0.82 | ||||
QGEN | Qiagen NV | 0.71 | ||||
NEOG | Neogen | 0.69 | ||||
BDSX | Biodesix | 0.67 | ||||
MTD | Mettler Toledo | 0.68 | ||||
SHC | Sotera Health | 0.74 | ||||
CRL | Charles River | 0.97 | ||||
TWST | Twist Bioscience | 1.10 | ||||
ICLR | ICON PLC | 1.46 | ||||
ACRS | Aclaris Therapeutics | 1.60 |
Check out NeoGenomics Hype Analysis, NeoGenomics Correlation and NeoGenomics Performance. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.